Type 2 diabetes and prediabetes affect more than half a billion people worldwide … and that number continues to rise.
In many cases, current management strategies — from lifestyle changes to medication — address the condition effectively.
But for many patients, achieving and maintaining glycaemic control remains a persistent challenge.
The question of what else might be driving metabolic dysregulation, and what else might be done about it, remains open.
The gut microbiome is increasingly implicated in this picture. A growing body of research links gut microbiome composition to insulin sensitivity, glucose metabolism and systemic inflammation, all of which are central to the development and progression of type 2 diabetes.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Nutraceutical Business Review.
Subscribe now Already a subscriber? Sign in here.
